Celsis International (UK) allies with Nova Biomedical
This article was originally published in Clinica
Executive Summary
Celsis International (UK) has established a manufacturing and product development alliance with US producer of clinical diagnostic systems Nova Biomedical. Nova will manufacture Celsis' microbial colony counter, the Scan500 system, in bulk, with the first instruments expected to be produced by May this year. The US company will also collaborate in the development and manufacture of Celsis' rapid contamination monitoring systems. A supplier of analytical systems to companies such as Abbott and Baxter, Nova has a manufacturing facility in Waltham, Massachusetts.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.